Evidence map›Paper›PMID 41386727›Full record

ArticleInternational journal of cancer2026

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study.

Ylva Naeser, Rasmus Mikiver, Karolin Isaksson, Mats Lambe, Gustav J Ullenhag

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ylva NaeserDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Rasmus MikiverDepartment of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Karolin IsakssonDepartment of Surgery, Skåne University Hospital, Kristianstad, Sweden.ORCID https://orcid.org/0000-0003-3690-5680
Mats LambeDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Gustav J UllenhagDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-4949-3267

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most cutaneous malignant melanomas (CMMs) are thin (≤1.0 mm, stage T1) with an expected 10-year melanoma-specific survival of 93%-97%. The incidence of CMM is higher in groups with high socioeconomic status (SES). We aimed to assess overall survival (OS) and detailed characteristics in individuals with thin CMM as compared to the general population matched on age, sex, and county of residence. Matched cohort study comprising patients diagnosed between 2001 and 2018 with thin CMM (cases) and melanoma-free comparators from the general population. Patients and comparators were identified in the Malignant Melanoma Data Base Sweden. Multivariable Cox regression analyses were applied to compare the mortality risk for cases and comparators with adjustments for SES and comorbidities. We identified 25,843 cases and 127,383 comparators. Cases had higher SES and less comorbidity. No significant differences in OS were found. However, in the T1a subgroup, comprising 16,941 cases, the 5-year OS was significantly better than in comparators (n = 83,510) (92.5% (95% CI 92.1%-93.0%) versus 91.1% (95% CI 90.8%-91.3%), p <.001). The adjusted mortality risk was slightly higher for the whole T1 group (HR 1.05, 95% CI 1.01-1.09), while no difference was found for the T1a subgroup. Deaths attributed to cardiovascular disease, dementia, and chronic obstructive pulmonary disease were less common in CMM patients. Patients diagnosed with thin CMM have an OS similar to or even better than the general population since they are at a lower risk of death from other diseases, likely reflecting socioeconomic and lifestyle factors.

Indexed as

MelanomaSkin NeoplasmsAdultAgedAged, 80 and overCohort StudiesComorbidityCutaneous Malignant MelanomaFemaleHumansMaleMiddle AgedNeoplasm StagingSocial ClassSurvival RateSwedencohort studiescomorbiditymelanoma, cutaneous malignantsocioeconomic factorssurvival

Identifiers

PMID41386727
PMCPMC12996739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.